Search

Your search keyword '"Wei, Andrew"' showing total 1,575 results
Start Over Author "Wei, Andrew"
1,575 results on '"Wei, Andrew"'

51. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

Author

Larson, Richard A., Mandrekar, Sumithra J., Huebner, Lucas J., Sanford, Ben L., Laumann, Kristina, Geyer, Susan, Bloomfield, Clara D., Thiede, Christian, Prior, Thomas W., Döhner, Konstanze, Marcucci, Guido, Voso, Maria Teresa, Klisovic, Rebecca B., Galinsky, Ilene, Wei, Andrew H., Sierra, Jorge, Sanz, Miguel A., Brandwein, Joseph M., de Witte, Theo, Niederwieser, Dietger, Appelbaum, Frederick R., Medeiros, Bruno C., Tallman, Martin S., Krauter, Jürgen, Schlenk, Richard F., Ganser, Arnold, Serve, Hubert, Ehninger, Gerhard, Amadori, Sergio, Gathmann, Insa, Döhner, Hartmut, and Stone, Richard M.

Published
2021
Full Text
View/download PDF

56. Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models

Author

Morrish, Emma, Copeland, Anthony, Moujalled, Donia M., Powell, Jason A., Silke, Natasha, Lin, Ann, Jarman, Kate E., Sandow, Jarrod J., Ebert, Gregor, Mackiewicz, Liana, Beach, Jessica A., Christie, Elizabeth L., Lewis, Alexander C., Pomilio, Giovanna, Fischer, Karla C., MacPherson, Laura, Bowtell, David D.L., Webb, Andrew I., Pellegrini, Marc, Dawson, Mark A., Pitson, Stuart M., Wei, Andrew H., Silke, John, and Brumatti, Gabriela

Published
2020
Full Text
View/download PDF

57. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

Author

Voso, Maria Teresa, Larson, Richard A., Jones, Dan, Marcucci, Guido, Prior, Thomas, Krauter, Jürgen, Heuser, Michael, Lavorgna, Serena, Nomdedeu, Josep, Geyer, Susan M., Walker, Alison, Wei, Andrew H., Sierra, Jorge, Sanz, Miguel A., Brandwein, Joseph M., de Witte, Theo M., Jansen, Joop H., Niederwieser, Dietger, Appelbaum, Frederick R., Medeiros, Bruno C., Tallman, Martin S., Schlenk, Richard F., Ganser, Arnold, Amadori, Sergio, Cheng, Yuan, Chen, YinMiao, Pallaud, Celine, Du, Ling, Piciocchi, Alfonso, Ehninger, Gerhard, Byrd, John, Thiede, Christian, Döhner, Konstanze, Stone, Richard M., Döhner, Hartmut, Bloomfield, Clara D., and Lo-Coco, Francesco

Published
2020
Full Text
View/download PDF

58. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Author

Montesinos, Pau, Roboz, Gail J., Bulabois, Claude-Eric, Subklewe, Marion, Platzbecker, Uwe, Ofran, Yishai, Papayannidis, Cristina, Wierzbowska, Agnieszka, Shin, Ho Jin, Doronin, Vadim, Deneberg, Stefan, Yeh, Su-Peng, Ozcan, Mehmet Ali, Knapper, Steven, Cortes, Jorge, Pollyea, Daniel A., Ossenkoppele, Gert, Giralt, Sergio, Döhner, Hartmut, Heuser, Michael, Xiu, Liang, Singh, Indrajeet, Huang, Fei, Larsen, Julie S., and Wei, Andrew H.

Published
2021
Full Text
View/download PDF

59. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Author

Zeidan, Amer M, Boddu, Prajwal C, Patnaik, Mrinal M, Bewersdorf, Jan Philipp, Stahl, Maximilian, Rampal, Raajit K, Shallis, Rory, Steensma, David P, Savona, Michael R, Sekeres, Mikkael A, Roboz, Gail J, DeAngelo, Daniel J, Schuh, Andre C, Padron, Eric, Zeidner, Joshua F, Walter, Roland B, Onida, Francesco, Fathi, Amir, DeZern, Amy, Hobbs, Gabriela, Stein, Eytan M, Vyas, Paresh, Wei, Andrew H, Bowen, David T, Montesinos, Pau, Griffiths, Elizabeth A, Verma, Amit K, Keyzner, Alla, Bar-Natan, Michal, Navada, Shyamala C, Kremyanskaya, Marina, Goldberg, Aaron D, Al-Kali, Aref, Heaney, Mark L, Nazha, Aziz, Salman, Huda, Luger, Selina, Pratz, Keith W, Konig, Heiko, Komrokji, Rami, Deininger, Michael, Cirici, Blanca Xicoy, Bhatt, Vijaya Raj, Silverman, Lewis R, Erba, Harry P, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Wang, Eunice S, Tallman, Martin S, Stone, Richard M, and Mascarenhas, John

Published
2020
Full Text
View/download PDF

60. A Partnership with Project 25: learning from the chronically homeless and the people who seek to improve their care

Author

Wei, Andrew

Abstract

By listening to the stories of chronically homeless patients and the community leaders who care deeply about them, I learned a tremendous amount about how our current health system is ill-equipped to address many patient needs, especially the social determinants of health. I learned how powerful it is to talk to patients outside of the hospital in humanizing them and influencing our own attitudes and biases. Given medical students’ limited exposure to homeless patients outside of the hospital, partnering with community hotspotting and housing-first initiatives is a valuable experience for changing future physician attitudes towards the homeless and learning a tremendous amount about our health and social support systems.

Published
2016

61. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

Author

Brunner, Andrew M., primary, Esteve, Jordi, additional, Porkka, Kimmo, additional, Knapper, Steve, additional, Traer, Elie, additional, Scholl, Sebastian, additional, Garcia‐Manero, Guillermo, additional, Vey, Norbert, additional, Wermke, Martin, additional, Janssen, Jeroen J. W. M., additional, Narayan, Rupa, additional, Fleming, Shaun, additional, Loo, Sun, additional, Tovar, Natalia, additional, Kontro, Mika, additional, Ottmann, Oliver G., additional, Naidu, Purushotham, additional, Sun, Haiying, additional, Han, May, additional, White, Roisin, additional, Zhang, Na, additional, Mohammed, Anisa, additional, Sabatos‐Peyton, Catherine A., additional, Steensma, David P., additional, Rinne, Mikael L., additional, Borate, Uma M., additional, and Wei, Andrew H., additional

Published
2023
Full Text
View/download PDF

62. Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML‐001

Author

Ravandi, Farhad, primary, Döhner, Hartmut, additional, Wei, Andrew H., additional, Montesinos, Pau, additional, Pfeilstöcker, Michael, additional, Papayannidis, Cristina, additional, Lai, Yinzhi, additional, Wang, Kefeng, additional, See, Wendy L., additional, de Menezes, Daniel Lopes, additional, Petrlik, Erica, additional, Prebet, Thomas, additional, and Roboz, Gail J., additional

Published
2023
Full Text
View/download PDF

65. BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals

Author

Srivastava, Rahul, Cao, Zhipeng, Nedeva, Christina, Naim, Samara, Bachmann, Daniel, Rabachini, Tatiana, Gangoda, Lahiru, Shahi, Sanjay, Glab, Jason, Menassa, Joseph, Osellame, Laura, Nelson, Tao, Fernandez-Marrero, Yuniel, Brown, Fiona, Wei, Andrew, Ke, Francine, O’Reilly, Lorraine, Doerflinger, Marcel, Allison, Cody, Kueh, Andrew, Ramsay, Rob, Smith, Brian J., Mathivanan, Suresh, Kaufmann, Thomas, and Puthalakath, Hamsa

Published
2019

66. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Author

Ravandi, Farhad, Roboz, Gail J., Wei, Andrew H., Döhner, Hartmut, Pocock, Christopher, Selleslag, Dominik, Montesinos, Pau, Sayar, Hamid, Musso, Maurizio, Figuera-Alvarez, Angela, Safah, Hana, Tse, William, Sohn, Sang Kyun, Hiwase, Devendra, Chevassut, Timothy, Pierdomenico, Francesca, La Torre, Ignazia, Skikne, Barry, Bailey, Rochelle, Zhong, Jianhua, Beach, C. L., and Dombret, Herve

Published
2021
Full Text
View/download PDF

67. Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

Author

Wei, Andrew H., Panayiotidis, Panayiotis, Montesinos, Pau, Laribi, Kamel, Ivanov, Vladimir, Kim, Inho, Novak, Jan, Stevens, Don A., Fiedler, Walter, Pagoni, Maria, Bergeron, Julie, Ting, Stephen B., Hou, Jing-Zhou, Anagnostopoulos, Achilles, McDonald, Andrew, Murthy, Vidhya, Yamauchi, Takahiro, Wang, Jianxiang, Chyla, Brenda, Sun, Yan, Jiang, Qi, Mendes, Wellington, Hayslip, John, and DiNardo, Courtney D.

Published
2021
Full Text
View/download PDF

68. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

Author

Wei, Andrew H., Panayiotidis, Panayiotis, Montesinos, Pau, Laribi, Kamel, Ivanov, Vladimir, Kim, Inho, Novak, Jan, Stevens, Don A., Fiedler, Walter, Pagoni, Maria, Bergeron, Julie, Ting, Stephen B., Hou, Jing-Zhou, Anagnostopoulos, Achilles, McDonald, Andrew, Murthy, Vidhya, Yamauchi, Takahiro, Wang, Jianxiang, Chyla, Brenda, Sun, Yan, Jiang, Qi, Mendes, Wellington, Hayslip, John, and DiNardo, Courtney D.

Published
2021
Full Text
View/download PDF

71. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Author

Ravandi, Farhad, Ritchie, Ellen K, Sayar, Hamid, Lancet, Jeffrey E, Craig, Michael D, Vey, Norbert, Strickland, Stephen A, Schiller, Gary J, Jabbour, Elias, Erba, Harry P, Pigneux, Arnaud, Horst, Heinz-August, Recher, Christian, Klimek, Virginia M, Cortes, Jorge, Roboz, Gail J, Odenike, Olatoyosi, Thomas, Xavier, Havelange, Violaine, Maertens, Johan, Derigs, Hans-Günter, Heuser, Michael, Damon, Lloyd, Powell, Bayard L, Gaidano, Gianluca, Carella, Angelo-Michele, Wei, Andrew, Hogge, Donna, Craig, Adam R, Fox, Judith A, Ward, Renee, Smith, Jennifer A, Acton, Gary, Mehta, Cyrus, Stuart, Robert K, and Kantarjian, Hagop M

Subjects
Humans, Neoplasm Recurrence, Local, Thiazoles, Naphthyridines, Cytarabine, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Treatment Outcome, Remission Induction, Double-Blind Method, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Leukemia, Myeloid, Acute, Kaplan-Meier Estimate, Clinical Research, Cancer, Clinical Trials and Supportive Activities, Hematology, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundSafe and effective treatments are urgently needed for patients with relapsed or refractory acute myeloid leukaemia. We investigated the efficacy and safety of vosaroxin, a first-in-class anticancer quinolone derivative, plus cytarabine in patients with relapsed or refractory acute myeloid leukaemia.MethodsThis phase 3, double-blind, placebo-controlled trial was undertaken at 101 international sites. Eligible patients with acute myeloid leukaemia were aged 18 years of age or older and had refractory disease or were in first relapse after one or two cycles of previous induction chemotherapy, including at least one cycle of anthracycline (or anthracenedione) plus cytarabine. Patients were randomly assigned 1:1 to vosaroxin (90 mg/m(2) intravenously on days 1 and 4 in a first cycle; 70 mg/m(2) in subsequent cycles) plus cytarabine (1 g/m(2) intravenously on days 1-5) or placebo plus cytarabine through a central interactive voice system with a permuted block procedure stratified by disease status, age, and geographical location. All participants were masked to treatment assignment. The primary efficacy endpoint was overall survival and the primary safety endpoint was 30-day and 60-day all-cause mortality. Efficacy analyses were done by intention to treat; safety analyses included all treated patients. This study is registered with ClinicalTrials.gov, number NCT01191801.FindingsBetween Dec 17, 2010, and Sept 25, 2013, 711 patients were randomly assigned to vosaroxin plus cytarabine (n=356) or placebo plus cytarabine (n=355). At the final analysis, median overall survival was 7·5 months (95% CI 6·4-8·5) in the vosaroxin plus cytarabine group and 6·1 months (5·2-7·1) in the placebo plus cytarabine group (hazard ratio 0·87, 95% CI 0·73-1·02; unstratified log-rank p=0·061; stratified p=0·024). A higher proportion of patients achieved complete remission in the vosaroxin plus cytarabine group than in the placebo plus cytarabine group (107 [30%] of 356 patients vs 58 [16%] of 355 patients, p

Published
2015

75. MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program

Author

Zeidan, Amer M., Al-Kali, Aref, Borate, Uma, Cluzeau, Thomas, DeZern, Amy E., Esteve, Jordi, Giagounidis, Aristoteles, Kobata, Krissy, Lyons, Roger, Platzbecker, Uwe, Sallman, David A., Santini, Valeria, Sanz, Guillermo F., Sekeres, Mikkael A., Wei, Andrew H., Xiao, Zhijian, Van Hoef, Marlies, Nourry-Boulot, Claire, Sadek, Islam, Ma, Fei, Iordan, Angelica, Sabo, John, and Garcia-Manero, Guillermo

Published
2022
Full Text
View/download PDF

77. AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

Author

DiNardo, Courtney D., de Botton, Stéphane, Risueño, Alberto, Schuh, Andre C., Löwenberg, Bob, Kim, Hee-Je, Vyas, Paresh, Wei, Andrew H., Stein, Eytan M., Döhner, Hartmut, Fathi, Amir T., Martin-Regueira, Patricia, Taningco, Lilia, Bluemmert, Iryna, Yu, Xin, See, Wendy L., and Hasan, Maroof

Published
2022
Full Text
View/download PDF

79. Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML‐001.

Author

Ravandi, Farhad, Döhner, Hartmut, Wei, Andrew H., Montesinos, Pau, Pfeilstöcker, Michael, Papayannidis, Cristina, Lai, Yinzhi, Wang, Kefeng, See, Wendy L., de Menezes, Daniel Lopes, Petrlik, Erica, Prebet, Thomas, and Roboz, Gail J.

Subjects
ACUTE myeloid leukemia, SURVIVAL rate, OVERALL survival, HEMATOPOIETIC stem cells, TERMINATION of treatment
Abstract

Summary: In the phase 3 QUAZAR AML‐001 trial (NCT01757535) of patients with acute myeloid leukaemia (AML) in remission following intensive chemotherapy (IC) and ineligible for haematopoietic stem cell transplant (HSCT), oral azacitidine (Oral‐AZA) maintenance significantly prolonged overall survival (OS) versus placebo. The impact of subsequent treatment following maintenance has not been evaluated. In this post hoc analysis, OS was estimated for patients who received subsequent AML therapy, and by regimen received (IC or lower‐intensity therapy). First subsequent therapy (FST) was administered after treatment discontinuation in 134/238 Oral‐AZA and 173/234 placebo patients. OS from randomization in patients who received FST after Oral‐AZA versus placebo was 17.8 versus 12.9 months (HR: 0.82 [95% CI: 0.64–1.04], median follow‐up: 56.7 months); OS from FST was similar between arms. Among patients who received injectable hypomethylating agents as FST, median OS was 8.2 versus 4.9 months in the Oral‐AZA versus placebo groups (HR: 0.66 [95% CI: 0.41–1.06]). Forty‐eight patients (16/238 Oral‐AZA, 32/234 placebo) received HSCT following treatment discontinuation, including six Oral‐AZA patients still in first remission; Oral‐AZA OS benefit persisted when censoring these patients. Oral‐AZA maintenance can prolong AML remission duration without negatively impacting survival outcomes after salvage therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

80. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel

Author

Ravandi, Farhad, primary, Cloos, Jacqueline, additional, Buccisano, Francesco, additional, Dillon, Richard, additional, Döhner, Konstanze, additional, Freeman, Sylvie D., additional, Hourigan, Christopher S., additional, Ossenkoppele, Gerrit J., additional, Roboz, Gail J., additional, Subklewe, Marion, additional, Thiede, Christian, additional, Arnhardt, Isabell, additional, Valk, Peter J. M., additional, Venditti, Adriano, additional, Wei, Andrew H., additional, Walter, Roland B., additional, and Heuser, Michael, additional

Published
2023
Full Text
View/download PDF

84. POSTER: AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)

Author

Fleming, Shaun, primary, Roboz, Gail J., additional, Fathi, Amir T., additional, Zhang, Tian Y., additional, Wei, Andrew, additional, Carraway, Hetty E., additional, Holes, Leanne, additional, Petrlik, Erica, additional, Prebet, Thomas, additional, Menezes, Daniel L., additional, Bluemmert, Iryna, additional, Sun, Hao, additional, and Ravandi, Farhad, additional

Published
2023
Full Text
View/download PDF

85. AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)

Author

Fleming, Shaun, primary, Roboz, Gail J., additional, Fathi, Amir T., additional, Zhang, Tian Y., additional, Wei, Andrew, additional, Carraway, Hetty E., additional, Holes, Leanne, additional, Petrlik, Erica, additional, Prebet, Thomas, additional, Menezes, Daniel L., additional, Bluemmert, Iryna, additional, Sun, Hao, additional, and Ravandi, Farhad, additional

Published
2023
Full Text
View/download PDF

87. Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy

Author

Othman, Jad, primary, Tiong, Ing Soo, additional, O'Nions, Jenny, additional, Dennis, Mike, additional, Mokretar, Katya, additional, Ivey, Adam, additional, Austin, Michael James, additional, Latif, Annie-Louise, additional, Amer, Mariam, additional, Chan, Wei Yee, additional, Crawley, Charles R, additional, Crolla, Francesca, additional, Cross, Joe Wilson, additional, Dang, Raymond, additional, Elliot, Johnathon, additional, Fong, Chun Yew, additional, Galli, Sofia, additional, Gallipoli, Paolo, additional, Hogan, Francesca, additional, Kalkur, Pallavi, additional, Khan, Anjum Bashir, additional, Krishnamurthy, Pramila, additional, Laurie, John, additional, Loo, Sun, additional, Marshall, Scott, additional, Mehta, Priyanka, additional, Murthy, Vidhya, additional, Nagumantry, Sateesh, additional, Pillai, Srinivas, additional, Potter, Nicola, additional, Sellar, Rob S., additional, Taylor, Tom, additional, Zhao, Rui, additional, Russell, Nigel H., additional, Wei, Andrew H., additional, and Dillon, Richard, additional

Published
2023
Full Text
View/download PDF

88. P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS

Author

Lopes De Menezes, Daniel, primary, Roboz, Gail, additional, Döhner, Hartmut, additional, Wei, Andrew, additional, Teresa Voso, Maria, additional, Schuh, Andre, additional, See, Wendy L., additional, Ugidos, Manuel, additional, Amzallag, Arnaud, additional, Risueño, Alberto, additional, H. Eng, Kevin, additional, Nvs Suragani, Rajasekhar, additional, Skikne, Barry, additional, Beach, CL, additional, Prebet, Thomas, additional, and Gandhi, Anita, additional

Published
2023
Full Text
View/download PDF

89. P365: SEQUENTIAL BLINATUMOMAB WITH REDUCED INTENSITY CHEMOTHERAPY FOR OLDER ADULTS WITH NEWLY DIAGNOSED PH- B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA – FINAL RESULTS OF THE ALLG ALL08 STUDY

Author

Fleming, Shaun, primary, Reynolds, John, additional, Bajel, Ashish, additional, Venn, Nicola, additional, Kwan, John, additional, Moore, John, additional, Yeung, David, additional, Pati, Nalini, additional, Leahy, Michael, additional, Kollipara, Sushma, additional, Verner, Emma, additional, Berkahn, Leanne, additional, Sutton, Rosemary, additional, Wei, Andrew, additional, and Greenwood, Matthew, additional

Published
2023
Full Text
View/download PDF

90. P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA

Author

Fleming, Shaun, primary, Roboz, Gail, additional, T. Fathi, Amir, additional, Y. Zhang, Tian, additional, Wei, Andrew, additional, Carraway, Hetty, additional, Holes, Leanne, additional, Petrlik, Erica, additional, Prebet, Thomas, additional, Lopes De Menezes, Daniel, additional, Bluemmert, Iryna, additional, Sun, Hao, additional, and Ravandi, Farhad, additional

Published
2023
Full Text
View/download PDF

92. Updates in classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium of MDS (icMDS)

Author

Stahl, Maximilian, primary, Bewersdorf, Jan Philipp, additional, Xie, Zhuoer, additional, Porta, Matteo Giovanni Della, additional, Komrokji, Rami, additional, Xu, Mina L., additional, Abdel-Wahab, Omar, additional, Taylor, Justin, additional, Steensma, David P., additional, Starczynowski, Daniel T., additional, Sekeres, Mikkael A., additional, Sanz, Guillermo, additional, Sallman, David A., additional, Roboz, Gail J., additional, Platzbecker, Uwe, additional, Patnaik, Mrinal M., additional, Padron, Eric, additional, Odenike, Olatoyosi, additional, Nimer, Stephen D., additional, Nazha, Aziz, additional, Majeti, Ravi, additional, Loghavi, Sanam, additional, Little, Richard F., additional, List, Alan F., additional, Kim, Tae Kon, additional, Hourigan, Christopher S., additional, Hasserjian, Robert P., additional, Halene, Stephanie, additional, Griffiths, Elizabeth A., additional, Gore, Steven D., additional, Greenberg, Peter, additional, Figueroa, Maria E., additional, Fenaux, Pierre, additional, Efficace, Fabio, additional, DeZern, Amy E., additional, Daver, Naval G., additional, Churpek, Jane E., additional, Carraway, Hetty E., additional, Buckstein, Rena, additional, Brunner, Andrew M., additional, Boultwood, Jacqueline, additional, Borate, Uma, additional, Bejar, Rafael, additional, Bennett, John M., additional, Wei, Andrew H., additional, Santini, Valeria, additional, Savona, Michael R., additional, and Zeidan, Amer M., additional

Published
2023
Full Text
View/download PDF

93. P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE

Author

Sharon, David, primary, Jung, Paul, additional, Sun, Yan, additional, Feng, Weiguo, additional, Yang, Ziping, additional, Robinson, Valerie, additional, Mitra, Diya, additional, Liu, Wei, additional, Zheng, Pingping, additional, Uziel, Tami, additional, Lam, Lloyd, additional, Minden, Mark, additional, Ross, Jeremy, additional, Mendes, Wellington, additional, Potluri, Jalaja, additional, Wei, Andrew, additional, Konopleva, Marina, additional, Dail, Monique, additional, Chyla, Brenda, additional, and Epling-Burnette, Pk, additional

Published
2023
Full Text
View/download PDF

94. P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL

Author

Lopes De Menezes, Daniel, primary, Wei, Andrew, additional, Döhner, Hartmut, additional, Roboz, Gail, additional, Teresa Voso, Maria, additional, Schuh, Andre, additional, See, Wendy L., additional, Ugidos, Manuel, additional, Amzallag, Arnaud, additional, Risueño, Alberto, additional, Kyriakopoulos, Charalampos, additional, Nvs Suragani, Rajasekhar, additional, Skikne, Barry, additional, Beach, CL, additional, Prebet, Thomas, additional, and Gandhi, Anita, additional

Published
2023
Full Text
View/download PDF

95. Data from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia

Author

Sabatier, Marie, primary, Birsen, Rudy, primary, Lauture, Laura, primary, Mouche, Sarah, primary, Angelino, Paolo, primary, Dehairs, Jonas, primary, Goupille, Léa, primary, Boussaid, Ismael, primary, Heiblig, Maël, primary, Boet, Emeline, primary, Sahal, Ambrine, primary, Saland, Estelle, primary, Santos, Juliana C., primary, Armengol, Marc, primary, Fernández-Serrano, Miranda, primary, Farge, Thomas, primary, Cognet, Guillaume, primary, Simonetta, Federico, primary, Pignon, Corentin, primary, Graffeuil, Antoine, primary, Mazzotti, Céline, primary, Avet-Loiseau, Hervé, primary, Delos, Océane, primary, Bertrand-Michel, Justine, primary, Chedru, Amélie, primary, Dembitz, Vilma, primary, Gallipoli, Paolo, primary, Anstee, Natasha S., primary, Loo, Sun, primary, Wei, Andrew H., primary, Carroll, Martin, primary, Goubard, Armelle, primary, Castellano, Rémy, primary, Collette, Yves, primary, Vergez, François, primary, Mansat-De Mas, Véronique, primary, Bertoli, Sarah, primary, Tavitian, Suzanne, primary, Picard, Muriel, primary, Récher, Christian, primary, Bourges-Abella, Nathalie, primary, Granat, Fanny, primary, Kosmider, Olivier, primary, Sujobert, Pierre, primary, Colsch, Benoit, primary, Joffre, Carine, primary, Stuani, Lucille, primary, Swinnen, Johannes V., primary, Guillou, Hervé, primary, Roué, Gael, primary, Hakim, Nawad, primary, Dejean, Anne S., primary, Tsantoulis, Petros, primary, Larrue, Clément, primary, Bouscary, Didier, primary, Tamburini, Jerome, primary, and Sarry, Jean-Emmanuel, primary

Published
2023
Full Text
View/download PDF

96. Supplementary Information v.2 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia

Author

Sabatier, Marie, primary, Birsen, Rudy, primary, Lauture, Laura, primary, Mouche, Sarah, primary, Angelino, Paolo, primary, Dehairs, Jonas, primary, Goupille, Léa, primary, Boussaid, Ismael, primary, Heiblig, Maël, primary, Boet, Emeline, primary, Sahal, Ambrine, primary, Saland, Estelle, primary, Santos, Juliana C., primary, Armengol, Marc, primary, Fernández-Serrano, Miranda, primary, Farge, Thomas, primary, Cognet, Guillaume, primary, Simonetta, Federico, primary, Pignon, Corentin, primary, Graffeuil, Antoine, primary, Mazzotti, Céline, primary, Avet-Loiseau, Hervé, primary, Delos, Océane, primary, Bertrand-Michel, Justine, primary, Chedru, Amélie, primary, Dembitz, Vilma, primary, Gallipoli, Paolo, primary, Anstee, Natasha S., primary, Loo, Sun, primary, Wei, Andrew H., primary, Carroll, Martin, primary, Goubard, Armelle, primary, Castellano, Rémy, primary, Collette, Yves, primary, Vergez, François, primary, Mansat-De Mas, Véronique, primary, Bertoli, Sarah, primary, Tavitian, Suzanne, primary, Picard, Muriel, primary, Récher, Christian, primary, Bourges-Abella, Nathalie, primary, Granat, Fanny, primary, Kosmider, Olivier, primary, Sujobert, Pierre, primary, Colsch, Benoit, primary, Joffre, Carine, primary, Stuani, Lucille, primary, Swinnen, Johannes V., primary, Guillou, Hervé, primary, Roué, Gael, primary, Hakim, Nawad, primary, Dejean, Anne S., primary, Tsantoulis, Petros, primary, Larrue, Clément, primary, Bouscary, Didier, primary, Tamburini, Jerome, primary, and Sarry, Jean-Emmanuel, primary

Published
2023
Full Text
View/download PDF

97. Supplementary Figures S1-S22 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia

Author

Sabatier, Marie, primary, Birsen, Rudy, primary, Lauture, Laura, primary, Mouche, Sarah, primary, Angelino, Paolo, primary, Dehairs, Jonas, primary, Goupille, Léa, primary, Boussaid, Ismael, primary, Heiblig, Maël, primary, Boet, Emeline, primary, Sahal, Ambrine, primary, Saland, Estelle, primary, Santos, Juliana C., primary, Armengol, Marc, primary, Fernández-Serrano, Miranda, primary, Farge, Thomas, primary, Cognet, Guillaume, primary, Simonetta, Federico, primary, Pignon, Corentin, primary, Graffeuil, Antoine, primary, Mazzotti, Céline, primary, Avet-Loiseau, Hervé, primary, Delos, Océane, primary, Bertrand-Michel, Justine, primary, Chedru, Amélie, primary, Dembitz, Vilma, primary, Gallipoli, Paolo, primary, Anstee, Natasha S., primary, Loo, Sun, primary, Wei, Andrew H., primary, Carroll, Martin, primary, Goubard, Armelle, primary, Castellano, Rémy, primary, Collette, Yves, primary, Vergez, François, primary, Mansat-De Mas, Véronique, primary, Bertoli, Sarah, primary, Tavitian, Suzanne, primary, Picard, Muriel, primary, Récher, Christian, primary, Bourges-Abella, Nathalie, primary, Granat, Fanny, primary, Kosmider, Olivier, primary, Sujobert, Pierre, primary, Colsch, Benoit, primary, Joffre, Carine, primary, Stuani, Lucille, primary, Swinnen, Johannes V., primary, Guillou, Hervé, primary, Roué, Gael, primary, Hakim, Nawad, primary, Dejean, Anne S., primary, Tsantoulis, Petros, primary, Larrue, Clément, primary, Bouscary, Didier, primary, Tamburini, Jerome, primary, and Sarry, Jean-Emmanuel, primary

Published
2023
Full Text
View/download PDF

98. Supplementary Table S15 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia

Author

Sabatier, Marie, primary, Birsen, Rudy, primary, Lauture, Laura, primary, Mouche, Sarah, primary, Angelino, Paolo, primary, Dehairs, Jonas, primary, Goupille, Léa, primary, Boussaid, Ismael, primary, Heiblig, Maël, primary, Boet, Emeline, primary, Sahal, Ambrine, primary, Saland, Estelle, primary, Santos, Juliana C., primary, Armengol, Marc, primary, Fernández-Serrano, Miranda, primary, Farge, Thomas, primary, Cognet, Guillaume, primary, Simonetta, Federico, primary, Pignon, Corentin, primary, Graffeuil, Antoine, primary, Mazzotti, Céline, primary, Avet-Loiseau, Hervé, primary, Delos, Océane, primary, Bertrand-Michel, Justine, primary, Chedru, Amélie, primary, Dembitz, Vilma, primary, Gallipoli, Paolo, primary, Anstee, Natasha S., primary, Loo, Sun, primary, Wei, Andrew H., primary, Carroll, Martin, primary, Goubard, Armelle, primary, Castellano, Rémy, primary, Collette, Yves, primary, Vergez, François, primary, Mansat-De Mas, Véronique, primary, Bertoli, Sarah, primary, Tavitian, Suzanne, primary, Picard, Muriel, primary, Récher, Christian, primary, Bourges-Abella, Nathalie, primary, Granat, Fanny, primary, Kosmider, Olivier, primary, Sujobert, Pierre, primary, Colsch, Benoit, primary, Joffre, Carine, primary, Stuani, Lucille, primary, Swinnen, Johannes V., primary, Guillou, Hervé, primary, Roué, Gael, primary, Hakim, Nawad, primary, Dejean, Anne S., primary, Tsantoulis, Petros, primary, Larrue, Clément, primary, Bouscary, Didier, primary, Tamburini, Jerome, primary, and Sarry, Jean-Emmanuel, primary

Published
2023
Full Text
View/download PDF

99. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Author

Zeidan, Amer M., Platzbecker, Uwe, Bewersdorf, Jan Philipp, Stahl, Maximilian, Adès, Lionel, Borate, Uma, Bowen, David, Buckstein, Rena, Brunner, Andrew, Carraway, Hetty E., Daver, Naval, Díez-Campelo, Maria, de Witte, Theo, DeZern, Amy E., Efficace, Fabio, Garcia-Manero, Guillermo, Garcia, Jacqueline S., Germing, Ulrich, Giagounidis, Aristoteles, Griffiths, Elizabeth A., Hasserjian, Robert P., Hellström-Lindberg, Eva, Iastrebner, Marcelo, Komrokji, Rami, Kulasekararaj, Austin G., Malcovati, Luca, Miyazaki, Yasushi, Odenike, Olatoyosi, Santini, Valeria, Sanz, Guillermo, Scheinberg, Phillip, Stauder, Reinhard, van de Loosdrecht, Arjan A., Wei, Andrew H., Sekeres, Mikkael A., Fenaux, Pierre, Hematology, AII - Cancer immunology, AII - Inflammatory diseases, and CCA - Cancer biology and immunology

Subjects
All institutes and research themes of the Radboud University Medical Center, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
Abstract

Contains fulltext : 292382.pdf (Publisher’s version ) (Closed access) Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable clinical presentations and outcomes. The initial response criteria developed by the International Working Group (IWG) in 2000 have been used in clinical practice, clinical trials, regulatory reviews, and drug labels. Although the IWG criteria were revised in 2006 and 2018 (the latter focusing on lower-risk disease), limitations persist in their application to higher-risk MDS (HR-MDS) and their ability to fully capture the clinical benefits of novel investigational drugs or serve as valid surrogates for longer-term clinical end points (eg, overall survival). Further, issues related to the ambiguity and practicality of some criteria lead to variability in interpretation and interobserver inconsistency in reporting results from the same sets of data. Thus, we convened an international panel of 36 MDS experts and used an established modified Delphi process to develop consensus recommendations for updated response criteria that would be more reflective of patient-centered and clinically relevant outcomes in HR-MDS. Among others, the IWG 2023 criteria include changes in the hemoglobin threshold for complete remission (CR), the introduction of CR with limited count recovery and CR with partial hematologic recovery as provisional response criteria, the elimination of marrow CR, and specific recommendations for the standardization of time-to-event end points and the derivation and reporting of responses. The updated criteria should lead to a better correlation between patient-centered outcomes and clinical trial results in an era of multiple emerging new agents with novel mechanisms of action.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results